Figure 4.
(A) In vivo efficacy of degradable diblock copolymer–GEM conjugates and PTX conjugates against A2780 human ovarian tumor xenografts. Tumor cells (5 × 106/mouse) were inoculated subcutaneously on the back of nude mice, and administration started when the tumor size reached ~100–200 mm3 (n = 5). Tumor growth was inhibited by either monotherapy or combination therapy. Intravenous and intraperitoneal injections were conducted, respectively. The doses of conjugates (gemcitabine 5 mg/kg × 3 on days 0, 7, 14 and paclitaxel 20 mg/kg on day 0) are in drug equivalent. (B) Body-weight change.